Elaine O'Hara serves as the Executive Vice President and Chief Strategy Officer at Novavax, Inc., a biotechnology company focused on the discovery, development, and commercialization of innovative vaccines. In her role, O'Hara is responsible for overseeing the company's strategic initiatives, which includes identifying and evaluating potential partnerships, acquisitions, and other growth opportunities that align with Novavax's mission to protect global public health. Her strategic leadership has been instrumental in guiding Novavax through the complex landscape of vaccine development and market expansion. Prior to joining Novavax, O'Hara held several senior leadership positions in the pharmaceutical and biotechnology industries. She has a robust background in strategic planning, business development, and corporate strategy, which she has leveraged to drive growth and innovation at Novavax. O'Hara's career is marked by her ability to navigate the challenges of bringing new medical products to market, and her contributions have been pivotal in advancing Novavax's portfolio of vaccines, including their efforts in developing a COVID-19 vaccine. Her strategic vision and execution have helped position Novavax as a key player in the global fight against infectious diseases. O'Hara's achievements at Novavax include leading the company's strategic partnerships with various governments and international organizations, which have been crucial in the rapid development and distribution of Novavax's vaccines. Her expertise in forging alliances and her deep understanding of the regulatory and commercial landscapes have enabled Novavax to expand its reach and impact. Under her guidance, Novavax continues to pursue its goal of addressing unmet medical needs through the development of novel vaccines, reinforcing its commitment to improving global health outcomes.